Can a light therapy save failing kidney transplants?

NCT ID NCT04870437

Recruiting now Disease control Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a treatment called extracorporeal phototherapy (ECP) for people whose kidney transplants are failing due to chronic antibody-mediated rejection. ECP involves taking a patient's blood cells, treating them with a light-activated drug and UVA light, then returning them to the body to calm the immune system. The trial will enroll 30 adults to see if ECP can reduce harmful immune cells and help preserve the transplanted kidney.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extracorporeal phototherapy (ECP)
What this could lead to: If it works, this could offer a new treatment option to help prevent kidney transplant loss due to chronic rejection.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply broadly. The treatment's effectiveness is uncertain, and it involves a complex blood-processing procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

CHU Clermont Ferrand
RECRUITING

Clermont-Ferrand, France
CHU de STRASBOURG
RECRUITING

Strasbourg, France
Chu Besancon
RECRUITING

Besançon, France
Chu Saint Etienne
RECRUITING

Saint-Etienne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.